Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG dermatology business “Intendis”

Executive Summary

Schering AG names separate dermatology business group Intendis. Company will formally begin operations Jan. 1. U.S. headquarters in Montville, N.J. will house about 70 out of approximately 600 global Intendis employees. Managing Director Wolfgang Kehr will lead global headquarters in Berlin. U.S. management will include North & Latin America Marketing & Sales head Bernhard Schefter. Schering announced in June it was spinning off "non-core" businesses to focus on oncology (1"The Pink Sheet" June 21, 2004, p. 38)....

You may also be interested in...



Schering AG Makes Oncology A Primary Focus; Dermatology No Longer “Core”

Schering AG is establishing a new global oncology business unit that will be headquartered in the U.S

EMA Endorses Dexamethasone For COVID-19

Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel